Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563458 | 0.83 | HSP90AB1 (0.41) | MAPK14 | |
| SCHEMBL1065608 | 0.72 | MERTK (0.39) | MAPK14GABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL24373280 | 0.71 | TNKS (0.40) | MAPK14ALDH1A1KDM4E | |
| SCHEMBL3527724 | 0.66 | MAPK14 (0.60) | MAPK14ALDH1A1KDM4E | |
| SCHEMBL1065104 | 0.66 | HSP90AB1 (0.42) | MAPK14ALDH1A1KDM4E | |
| SCHEMBL29478904 | 0.65 | HTR7 (0.42) | MAPK14ALDH1A1 | |
| SCHEMBL24373057 | 0.65 | HTR7 (0.42) | MAPK14ALDH1A1 | |
| SCHEMBL1063998 | 0.65 | PPARG (0.43) | MAPK14ALDH1A1MERTK | |
| SCHEMBL1066143 | 0.64 | RXFP1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL24373060 | 0.64 | CTSA (0.32) | MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759486-B2 | Substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090105478-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105478-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | MAPK14 42/4885GABRA1 3564/4885GABRA5 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.